Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Glucotrack, Inc. GCTK

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-19.4M
$-15.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2019 · Revenue 0.2 · Net income 3.5
5.0M10.0M-2.5M-5.0M
2007201020132016201920222025
Compound annual growth
−30.2%
+28.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +28.3% a year over the five years to FY2019.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2019 · Operating 1685.6%
500%1000%1500%-5000%-10000%-15000%
200720162025
ROE
FY2023 · ROE -320.6%
-200%-400%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -417%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -15.3
-10M-20M
200720162025

Total assetsUSD 7.8M
EquityUSD 2.8M
CashUSD 7.4M
Current ratio1.61×

Equity funds 36% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GCTK, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B◌◌◌◌◌◌0.00.00.00.00.00.0◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EPS, diluted $−31.22−4106.00−34.18−0.290.260.190.02−4.74−1.87−1.08−1.150.37−1.95−0.52−0.46−0.700.30◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %——−320.6−138.9−57.5—————————−301.9——−516.6−293.8
Shares out B0.000.000.000.020.020.200.160.140.010.010.010.010.010.010.010.00◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 67 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image